Related Experiment Videos
Cytokine medicines in clinical practice: current issues.
Theresa Barnes1, Robert J Moots, John Goodacre
1Department of Rheumatology, Academic Rheumatology Unit, University of Liverpool, UK.
Cytokine
|September 29, 2005
Summary
Cytokine medicines, used since 2000 for rheumatoid arthritis, have established treatment guidelines and improved understanding of inflammatory diseases. Ongoing research promises further advancements in this rapidly evolving field.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Cytokine medicines have been approved for rheumatoid arthritis treatment since 2000.
- Extensive clinical experience with these therapies has been gathered by the rheumatology community.
- The use of these medications has spurred significant system developments in rheumatology.
Purpose of the Study:
- To summarize the accumulated experience with cytokine medicines in rheumatoid arthritis treatment.
- To highlight the development of guidelines for monitoring long-term adverse events and efficacy.
- To discuss the role of cytokine medicines in understanding inflammatory disease pathogenesis.
Main Methods:
- Review of clinical experience and treatment guidelines for cytokine medicines.
- Utilization of the Biologics Register for monitoring long-term adverse events and efficacy.
- Analysis of the impact of cytokine therapies on understanding disease pathogenesis.
Main Results:
- Established guidelines for the use of cytokine medicines, including adverse event monitoring.
- Demonstrated the value of cytokine medicines as tools for probing disease pathogenesis.
- Significant system developments in rheumatology to facilitate the delivery of these therapies.
Conclusions:
- Cytokine medicines are valuable tools in managing rheumatoid arthritis and understanding inflammatory diseases.
- Ongoing vigilance and established guidelines ensure safe and effective long-term use.
- The field of cytokine therapeutics is rapidly expanding with new agents on the horizon.